Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Acronyms TITRATION
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2020 Results (n=15,038) of meta-analysis exploring angioedema in the 6 clinical trials (PARADIGM-HF, PIONEER, TITRATION, EVALUATE-HF & PARAGON-HF) and in real-world pharmacovigilance data, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
    • 22 Nov 2017 Results of post-hoc analysis assessing relationship between SBP and initiation and up-titration of sacubitril/valsartan published in the European Journal of Heart Failure
    • 12 May 2016 Results published in the European Journal of Heart Failure
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top